During the last session, Royalty Pharma plc (NASDAQ:RPRX)’s traded shares were 2.99 million, with the beta value of the company hitting 0.46. At the end of the trading day, the stock’s price was $29.19, reflecting an intraday gain of 1.64% or $0.47. The 52-week high for the RPRX share is $36.74, that puts it down -25.87 from that peak though still a striking 11.2% gain since the share price plummeted to a 52-week low of $25.92. The company’s market capitalization is $13.04B, and the average intraday trading volume over the past 10 days was 2.03 million shares, and the average trade volume was 2.65 million shares over the past three months.
Royalty Pharma plc (NASDAQ:RPRX) trade information
Royalty Pharma plc (RPRX) registered a 1.64% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.64% in intraday trading to $29.19, hitting a weekly high. The stock’s 5-day price performance is -3.89%, and it has moved by -1.85% in 30 days. Based on these gigs, the overall price performance for the year is -18.10%. The short interest in Royalty Pharma plc (NASDAQ:RPRX) is 12.65 million shares and it means that shorts have 4.01 day(s) to cover.
Royalty Pharma plc (RPRX) estimates and forecasts
Statistics show that Royalty Pharma plc has underperformed its competitors in share price, compared to the industry in which it operates. Royalty Pharma plc (RPRX) shares have gone up 9.53% during the last six months, with a year-to-date growth rate less than the industry average at -13.14% against 11.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -40.60% this quarter and then jump 9.50% in the quarter after that. In the rating firms’ projections, revenue will increase 11.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $665.57 million as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $608.46 million by the end of Jun 2024.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.23%. While earnings are projected to return -12.79% in 2024, the next five years will return 3.20% per annum.
RPRX Dividends
Royalty Pharma plc is due to release its next quarterly earnings between May 07 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Royalty Pharma plc is 0.81, with the dividend yield indicating at 2.77 percent, continuing the trend of increasing dividends in recent years.
Royalty Pharma plc (NASDAQ:RPRX)’s Major holders
Royalty Pharma plc insiders own 3.83% of total outstanding shares while institutional holders control 71.95%, with the float percentage being 74.81%. Morgan Stanley is the largest shareholder of the company, while 605 institutions own stock in it. As of Jun 29, 2023, the company held over 47.43 million shares (or 10.57% of all shares), a total value of $1.46 billion in shares.
The next largest institutional holding, with 38.85 million shares, is of Vanguard Group Inc’s that is approximately 8.65% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $1.19 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Royalty Pharma plc (RPRX) shares are Vanguard Total Stock Market Index Fund and Vanguard Mid-Cap Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 11.96 million shares. This amounts to just over 2.66 percent of the company’s overall shares, with a $367.69 million market value. The same data shows that the other fund manager holds slightly less at 8.83 million, or about 1.97% of the stock, which is worth about $271.44 million.
